NZ754944A - Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors - Google Patents

Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors

Info

Publication number
NZ754944A
NZ754944A NZ754944A NZ75494417A NZ754944A NZ 754944 A NZ754944 A NZ 754944A NZ 754944 A NZ754944 A NZ 754944A NZ 75494417 A NZ75494417 A NZ 75494417A NZ 754944 A NZ754944 A NZ 754944A
Authority
NZ
New Zealand
Prior art keywords
imidazo
pyrazine derivatives
pi3kdelta
inhibitors
disclosed
Prior art date
Application number
NZ754944A
Other languages
English (en)
Inventor
Zhiwei Wang
Jing Li
Haibo Zhao
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of NZ754944A publication Critical patent/NZ754944A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ754944A 2016-12-07 2017-12-07 Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors NZ754944A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016108897 2016-12-07
PCT/CN2017/114970 WO2018103688A1 (en) 2016-12-07 2017-12-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Publications (1)

Publication Number Publication Date
NZ754944A true NZ754944A (en) 2023-02-24

Family

ID=62491736

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ754944A NZ754944A (en) 2016-12-07 2017-12-07 Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors

Country Status (16)

Country Link
US (2) US11136323B2 (cg-RX-API-DMAC10.html)
EP (1) EP3551630A4 (cg-RX-API-DMAC10.html)
JP (2) JP7064495B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190091339A (cg-RX-API-DMAC10.html)
CN (2) CN114805366A (cg-RX-API-DMAC10.html)
AU (2) AU2017372377B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019011847A2 (cg-RX-API-DMAC10.html)
CA (1) CA3045959A1 (cg-RX-API-DMAC10.html)
EA (1) EA201991355A1 (cg-RX-API-DMAC10.html)
IL (2) IL266986B (cg-RX-API-DMAC10.html)
MX (1) MX394882B (cg-RX-API-DMAC10.html)
NZ (1) NZ754944A (cg-RX-API-DMAC10.html)
SG (1) SG10201912192RA (cg-RX-API-DMAC10.html)
TW (2) TWI762534B (cg-RX-API-DMAC10.html)
WO (1) WO2018103688A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201903286B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394882B (es) 2016-12-07 2025-03-24 Beigene Ltd Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
NZ761680A (en) * 2017-09-08 2023-03-31 Beigene Ltd Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
US20230011916A1 (en) * 2019-11-21 2023-01-12 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
JP2024521763A (ja) * 2021-05-27 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー Pi3kデルタ阻害剤の塩、その結晶形態、調製方法、及び使用
TW202327611A (zh) * 2021-09-14 2023-07-16 英屬開曼群島商百濟神州有限公司 使用btk抑制劑和p13激酶抑制劑的組合治療癌症之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
NZ596185A (en) * 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
US8653089B2 (en) 2011-02-09 2014-02-18 F. Hoffmann-La Roche Ag Heterocyclic compounds and methods of use
CA2860723A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
KR20160013204A (ko) * 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
MX394882B (es) 2016-12-07 2025-03-24 Beigene Ltd Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
NZ761680A (en) 2017-09-08 2023-03-31 Beigene Ltd Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors

Also Published As

Publication number Publication date
IL266986A (en) 2019-07-31
SG10201912192RA (en) 2020-02-27
ZA201903286B (en) 2021-01-27
JP7064495B2 (ja) 2022-05-10
TW202233190A (zh) 2022-09-01
AU2022203737A1 (en) 2022-06-23
US11725012B2 (en) 2023-08-15
MX2019006612A (es) 2019-08-01
US20220098202A1 (en) 2022-03-31
EP3551630A4 (en) 2020-07-15
IL290419B (en) 2022-10-01
IL266986B (en) 2022-03-01
WO2018103688A1 (en) 2018-06-14
EP3551630A1 (en) 2019-10-16
JP2022090051A (ja) 2022-06-16
CA3045959A1 (en) 2018-06-14
CN110267959B (zh) 2022-05-27
TWI762534B (zh) 2022-05-01
KR20190091339A (ko) 2019-08-05
TW201833113A (zh) 2018-09-16
MX394882B (es) 2025-03-24
EA201991355A1 (ru) 2019-11-29
IL290419B2 (en) 2023-02-01
AU2017372377A1 (en) 2019-07-18
JP2020500909A (ja) 2020-01-16
US11136323B2 (en) 2021-10-05
CN114805366A (zh) 2022-07-29
AU2017372377B2 (en) 2022-03-03
CN110267959A (zh) 2019-09-20
IL290419A (en) 2022-04-01
BR112019011847A2 (pt) 2019-10-29
US20190367523A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
NZ766835A (en) Pharmaceutical compounds
TN2022000039A1 (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
EP4365179A3 (en) Novel rapamycin derivatives
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
SA520411843B1 (ar) Trpc6 مشتقات بيريدين كربونيل والاستخدام الطبي لها كمثبطات
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX394882B (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
CR20220182A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592)
EP4233869A3 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MY199730A (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2021001096A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
SG10201806565SA (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed